Alacrita, a transatlantic life sciences consultancy firm, has appointed Pierre Dodion as an Associate Partner based in its Cambridge, MA office.
Dodion was formerly SVP, Corporate Development and Operations at ARIAD Pharmaceuticals and played a major role in the firm's expansion into Europe and its European launch of cancer treatment Iclusig, which was approved in 2013.
The appointment strengthens Alacrita’s US team and consolidates its position as a leading provider of expert advice to life science companies looking to develop, launch or partner their products in the European market.
Dodion trained as an oncologist in Belgium before working for Aventis, Novartis and Pfizer in the US, where he was responsible for the successful development and launch of a number of oncology drugs.
Alacrita’s London office is supported by a team of Associates across Europe, all of whom have broad life science industry experience and expertise. The firm supports clients across a range of functional disciplines, including clinical, regulatory, manufacturing, quality, strategic market access, commercial and M&A.
Dodion said: 'An increasing number of US life science companies are looking to commercialise their products themselves in Europe, but lack the in-house experience and expertise to do so effectively. Europe is a challenging market but represents the second-largest pharmaceutical region and influences drug prices around the world. Companies are able to maximise the value of their products outside the US by planning for European success early in clinical development; I’m looking forward to sharing my experience and insights with Alacrita’s clients.'
